





# Model protocol for national AMR surveillance Overview of work with priority countries

Egle Kudirkiene, DVM, PhD

Foodborne Infections (FBI)
Statens Serum Institut (SSI)

Midterm Network meeting, 2023 Copenhagen

# **Background**



Since 2005, all EU Member states are obliged to collect **relevant and comparable data** on Salmonella and Campylobacter <u>infections</u> in humans, food-related <u>outbreaks</u>, and the <u>occurrence of resistance to antimicrobials</u> (*Directive 2003/99/EC*)

- Monitoring of antimicrobial resistance should be carried out on a representative subset of isolates tested according to the harmonized EU protocol
- > The data should be reported to ECDC





# **Proposed national model protocol**

Proposed model protocol <u>covers the procedures</u> beginning **from**when isolates are obtained at the primary diagnostic
laboratories to the actual AMR testing

The proposed model protocol does not tell how to do surveillance but gives an input on aspects for consideration

Serves as a guide for the <u>development of national AMR</u>
<u>surveillance protocol</u> in each country



Service contract for the provision of EU networking and support for public health reference laboratory functions for antimicrobial resistance in Salmonella species and Campylobacter species in human samples

SC 2019 74 09

#### Deliverable T2.4

Model protocol for national surveillance of AMR in human Salmonella and Campylobacter infections

> Version no: 4 12 December 2022







Health and Digital Executive Agency





# Main aspects for consideration

### **Surveillance objectives**

Preferably in line with EU surveillance objectives

## National network of laboratories

- Clinical laboratories
- National reference laboratory in Public Health

### **Isolates for AMR testing**

> A substantial and representative proportion of the laboratory-confirmed cases in the country

## **AMR** testing and reporting

- > According to minimal and optimal requirements for reference diagnostics and characterisation
- A national system for capturing and analysing the AMR data


### **National network of laboratories**



#### Clinical laboratories

- primary diagnostic testing
- characterisation
- antimicrobial susceptibility testing

<u>Focus</u> on patient management and preventive services



#### The NRL

<u>Support</u> a national (sentinel) network of laboratories for the national AMR surveillance

- National capacity for isolation and further characterization for required quality of surveillance
- Agreements on isolate/sample/data selection and frequency of referral from clinical laboratories to the NRL



# Minimal and optimal requirements for reference testing

Table 1. Recommended minimum and optimal requirements for reference diagnostics and characterisation of Salmonella

Requirements	Serotyping	Antimicrobial resistance	Cluster detection
Minimum	Phenotypic or genotypic: common serovars	Phenotypic AST or genotypic AMR prediction	Not applicable*
Optimal	Phenotypic or genotypic: all serovars	Phenotypic AST and WGS-based AMR prediction**	WGS-based (e.g. cgMLST, wgMLST, SNP***)

<sup>\*</sup> if the NRL has not yet implemented any method for cluster detection, we recommend implementation of WGS-based cluster detection

Table 2. Recommended minimum and optimal requirements for reference diagnostics and characterisation of Campylobacter

Requirements	Species	Antimicrobial resistance	Cluster detection
Minimum	Phenotypic or genotypic: <i>C. jejuni, C. coli</i>	Phenotypic AST or genotypic AMR prediction	Not applicable*
Optimal	Phenotypic or genotypic: all species	Phenotypic AST and WGS-based AMR prediction**	WGS-based (e.g., cgMLST, wgMLST, SNP***)

<sup>\*</sup> if the NRL has not yet implemented any method for cluster detection, we recommend implementation of WGS-based cluster detection



Gaps in AMR testing was the basis for Priority countries selection

<sup>\*\*</sup> a defined proportion of isolates or selected isolates are periodically tested phenotypically to ensure detection of novel resistance mechanisms


<sup>\*\*\*</sup> cgMLST - core genome Multilocus Sequence Typing, wgMLST whole genome Multilocus Sequence Typing, SNP - Single Nucleotide Polymorphism

<sup>\*\*</sup> a defined proportion of isolates or selected isolates are periodically tested phenotypically to ensure detection of novel resistance mechanisms

<sup>\*\*\*</sup> cgMLST – core genome Multilocus Sequence Typing, wgMLST whole genome Multilocus Sequence Typing, SNP – Single Nucleotide Polymorphism

## **Priority countries team**







# Tailored priority countries support for capacity building for AMR surveillance 1/2



- Action plan for capacity building in NRL development and implementation
  - Based on five core functions of reference microbiology laboratory with the main focus on reference diagnostics and monitoring, alert and response







# Tailored priority countries support for capacity building for AMR surveillance 2/2



## ■ Support to NRLs for capacity building in clinical labs

- State-of-play reports on the capacity for *Salmonella* and *Campylobacter* detection and characterization in local/regional clinical laboratories





Local capacity building support

2023-2024



# Main achievements and challenges in Priority countries

Group A	AST	National surveillance network/ capacity building	Pilot WGS study	Routine use of WGS for surveillance
Country 1				
Country 2				
Country 3				
Country 4				
Country 5				
Country 6				

#### Main challenges:

- Representative sample
- Sample selection for WGS
- Bioinformatics infrastructure
- Bioinformatics skills
- Sustainability of WGS activities

Group B	AST	National surveillance network/ capacity building	Pilot WGS study	Routine use of WGS for surveillance
Country 7				
Country 8				
Country 9				
Country 10				
Country 11				
Country 12				

#### Main challenges:

- Prioritisation at the national level
- Funding
- Representative sample
- Access to WGS